Immunization of an individual against carcinoma and the preliminary stages thereof

Abstract

The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.

1 . A pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunizing an individual against carcinomas and the preliminary stages thereof as well as common auxiliary agents, wherein the cell cycle regulatory protein is a cyclin-dependent kinase inhibitor and the carcinomas are those of the upper respiratory tract or anogenital carcinomas.  
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the cyclin-dependent kinase inhibitor is a protein p15, p16, p18 or p19.  
     
     
         3 . The pharmaceutical composition according to  claim 1  or  2 , wherein the cell cycle regulatory protein is available in the form of one or more fragments.  
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein the fragment or fragments contain epitopes which can be detected by cytotoxic T cells and elicit a cytotoxic immune response.  
     
     
         5 . The pharmaceutical composition according to any of  claims 1  to  4 , wherein the anogenital carcinoma is a cervical carcinoma.  
     
     
         6 . Use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this for immunizing an individual against carcinomas and the preliminary stages thereof, wherein the cell cycle regulatory protein is a cyclin-dependent kinase inhibitor and the carcinomas are those of the upper respiratory tract and/or anogenital carcinomas.  
     
     
         7 . Use according to  claim 6 , wherein the cyclin-dependent kinase inhibitor is a protein p15, p16, p18 or p19.  
     
     
         8 . Use according to  claim 5  or  6 , wherein the cell cycle regulatory protein is available in the form of one or more fragments.  
     
     
         9 . Use according to  claim 8 , wherein the fragment or fragments contain epitopes which can be detected by cytotoxic T cells and elicit a cytotoxic immune response.  
     
     
         10 . Use according to any of  claims 6  to  9 , the anogenital carcinoma is a cervical carcinoma.